MIR9-3 and neoplasm: The MIR9-2 promoter was methylated in 5 out of 10 NBTs and 58 out of 101 tumours (p = 0.744) and MIR9-3 promoter in 4 out of 10 NBT and in 71 out of 101 tumours (p = 0.075) (Table S4).